All AbMole products are for research use only, cannot be used for human consumption.
Cilengitide is a molecule designed and synthesized at the Technical University Munich in collaboration with Merck KGaA in Darmstadt. Cilengitide binds to the activities of the αvβ3 and αvβ5 integrins, thereby inhibiting endothelial cell-cell interactions, endothelial cell-matrix interactions, and angiogenesis. Cilengitide (EMD 121974) could increase systemic RIT efficacy of therapy in a human breast cancer tumor model having mutant p53 and expressing bcl-2. Cilengitide is currently in clinical phase III for treatment of glioblastomas and in phase II for several other tumors.
Heliyon. 2023 Jun 29;e17841.
Cilengitide inhibits osteoclast adhesion through blocking the αvβ3-mediated FAK/Src signaling pathway
Cilengitide purchased from AbMole
Molecular Weight | 588.66 |
Formula | C27H40N8O7 |
CAS Number | 188968-51-6 |
Solubility (25°C) | DMSO: ≥ 45 mg/mL |
Storage | -20°C, dry, sealed |
Related Integrin Products |
---|
Volociximab
Volociximab (M200) is a chimeric human/murine IgG4 antibody IIA1 targeting integrin α5β1 (EC50=0.2 nM). Volociximab has antiangiogenic and antitumor activities and inhibits the proliferation of human umbilical vein vascular endothelial cells (HUVECs). |
GSK 3008348 hydrochloride
GSK 3008348 hydrochloride is a small molecule integrin αvβ6 antagonist. |
HSDVHK-NH2
HSDVHK-NH2 is an antagonist of the integrin αvβ3-vitronectin interaction, with an IC50 of 1.74 pg/mL (2.414 pM). |
LDV
LDV, a tripeptide, is a non-fluorescent analog of LDV-FITC. |
Cyclo(RADfK)
Cyclo(RADfK) is a selective α(v)β(3) integrin ligand that has been extensively used for research, therapy, and diagnosis of neoangiogenesis. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.